#ResearchSpeak & #ECTRIMS2017: late-breakers at ECTRIMS 2017

#
What do you think of the late-breaking news scientific programme at ECTRIMS next month? 



CoI: multiple

About the author

Prof G

Professor of Neurology, Barts & The London. MS & Preventive Neurology thinker, blogger, runner, vegetable gardener, husband, father, cook and wine & food lover.

12 comments

  • I'm very interested to learn the topline results of the Ibudilast trial. Have you seen anything that hints to success/failure?

  • Hardly late breaking for the Ozanimod trial (positive). It was announced by Cellgene as being positive on 25 March which was before the abstract deadline for the main meeting

    GNBca1 results were announced August (failure), so a boring 15 minutes

    MRI in primates is really going to get the juices going of your average neurologist

    MOG antibody induced disease is often an NMO-like condition#

    Does neurofilament levels reflect efficacy in RR disease…yes

    Fingolimod in peadiatric MS we can guess too

    • We all want to know about Ibudilast in Progressive MS but am a bit disappointed by the men in grey's choices our story is cracking

By Prof G

Translate

Categories

Recent Posts

Recent Comments

Archives